Opinion ID: 219633
Heading Depth: 2
Heading Rank: 2

Heading: Creative's '273 Patent

Text: Creative filed the application for the '273 Patent on April 30, 2003. Unlike the '373 Patent, which claims a genus of possible creatine salts, Creative's '273 Patent is narrower and covers only dicreatine malate compounds. Claims 1-3 cover a dicreatine malate compound and claims 4-10 cover methods of administering a dicreatine malate compound. Independent claim 1, representative of the compound claims, recites: 1. A dicreatine malate compound comprising approximately two creatine cations per one malic acid dianion. Independent claim 4, representative of the method claims, recites: 4. A method of increasing the production of adenosine triphosphate in a human body comprising administering to a subject a dicreatine malate compound comprising approximately two creatine cations per one malic acid dianion. The '273 Patent issued to Creative on October 31, 2006, about one month after the issuance of Starmark's '373 Patent. Creative's '273 Patent lists Derek Cornelius (Cornelius) and Gary Haynes (Haynes) as co-inventors.